This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Srivastava, M. Articles by Pollard, H. B. Search for Related Content PubMed PubMed Citation Articles by Srivastava, M. Articles by Pollard, H. B.

Prognostic Impact of ANX7-GTPase in Metastatic and HER2-Negative Breast Cancer Patients

¹ Department of Anatomy, Physiology and Genetics and Institute for Molecular Medicine, Uniformed Services University School of Medicine, Bethesda, Maryland; ² Institute for Pathology, University of Basel, Basel, Switzerland; ³ Laboratory of Pathology, Hematopathology Section, National Cancer Institute, NIH, Bethesda, Maryland; ⁴ Preventive Medicine and Biometrics, Uniformed Services University School of Medicine, Bethesda, Maryland; and ⁵ Section on Molecular Genetics, Cancer Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, Maryland

Purpose: ANX7-GTPase located on chromosome 10q21 is significantly altered and associated with hormone-refractory metastatic prostate cancers. Therefore, we investigated whether levels of ANX7 correlate with breast cancer progression and survival

Experimental Design: A diagnostic tumor tissue microarray containing 525 human breast tissue specimens at different stages of the disease was assayed for ANX7 using immunocytochemical methods with ANX7 monoclonal antibody. A separate prognostic tumor tissue microarray containing 553 human breast tissue specimens annotated with clinicopathological parameters was assayed for ANX7, HER2, estrogen receptor, progesterone receptor, and p53 protein.

Results: We report here for the first time that the expression of ANX7-GTPase is significantly enhanced and associated with the presence of metastatic disease (P < 0.0001) in the 525 human breast tissue specimens analyzed. Furthermore, using a separate 553 case retrospective prognostic tumor tissue microarray, we found that increased ANX7 expression is also significantly associated with poor overall patient survival (P < 0.014). This is particularly true when restricted to patients in whom the BRE clinical grade is 2 (P < 0.001) or for whom there is a lack of HER2 expression (P < 0.002). Finally, Cox regression analysis shows that as the expression of ANX7 rises, the probability of survival decreases by more than 10-fold for those patients with HER2-negative tumors. These latter patients represented 66% of the population affected with breast cancer in this study.

Conclusions: High levels of ANX7 in tumor correlate strongly with poor survival of HER2-negative patients and the most aggressive forms of breast cancer. This is the first study to demonstrate that ANX7 antibody has the potential for development into an in vivo diagnostic and therapeutic tool. This simple and reliable immunohistochemical assay may therefore become an important biomarker for metastatic breast cancer diagnosis and management of HER2-negative breast tumor patients.

This article has been cited by other articles:

				D. V. Rozanov, A. Y. Savinov, R. Williams, K. Liu, V. S. Golubkov, S. Krajewski, and A. Y. Strongin Molecular Signature of MT1-MMP: Transactivation of the Downstream Universal Gene Network in Cancer Cancer Res., June 1, 2008; 68(11): 4086 - 4096. [Abstract] [Full Text] [PDF]

				B. A. Babbin, W. Y. Lee, C. A. Parkos, L. M. Winfree, A. Akyildiz, M. Perretti, and A. Nusrat Annexin I Regulates SKCO-15 Cell Invasion by Signaling through Formyl Peptide Receptors J. Biol. Chem., July 14, 2006; 281(28): 19588 - 19599. [Abstract] [Full Text] [PDF]